[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

1-877-240-9479

Email address

information.center@astrazeneca.com

Condition

Breast Cancer; HER2-positive; Metastatic

Treatment type

Interventional

Investigational product

Pertuzumab

Phase

Phase 3

Sponsor

AstraZeneca

ClinicalTrials.gov identifier

NCT04784715

Study number

D967UC00001

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Patients must be ≥18 years of age
  2. Pathologically documented breast cancer that:
  3. is advanced or metastatic
  4. is locally assessed and prospectively centrally confirmed as HER2-positive (IHC3+ or ISH+)
  5. is documented by local testing as hormone receptor (HR)-positive or HR-negative disease in the metastatic setting
  6. No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer or only 1 previous line of endocrine therapy in the metastatic setting. Participants who have received chemotherapy or HER2-targeted therapy in the neo-adjuvant or adjuvant setting are eligible if > 6 months from treatment to metastatic diagnosis.
  7. Has protocol-defined adequate organ and bone marrow function
  8. ECOG performance status 0 or 1 Key
Exclusion criteria

  1. Ineligible for any of the agents on the study.
  2. Any substance abuse or other medical conditions that, in the investigator's opinion, may interfere with subject's participation or study results
  3. Patients with spinal cord compression or clinically active central nervous system metastases. Participants with clinically inactive brain metastases or treated brain metastases that are no longer symptomatic may be included in the study.
  4. Active or prior documented interstitial lung disease (ILD)/pneumonitis or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  5. Prior randomization or treatment in a previous trastuzumab deruxtecan study regardless of treatment arm assignment

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site